Professional
Added to YB: 2025-05-21
Pitch date: 2025-05-19
RXST [bullish]
RxSight, Inc.
-22.58%
current return
Author Info
No bio for this author
Company Info
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.
Market Cap
$400.1M
Pitch Price
$16.30
Price Target
25.00 (+98%)
Dividend
N/A
EV/EBITDA
-4.60
P/E
-11.07
EV/Sales
1.30
Sector
Health Care Equipment and Supplies
Category
growth
Wells Fargo Upgrades RxSight to Overweight, Raises Price Target to $25
$RXST: Wells Fargo upgraded to Overweight with $25 PT (from $17). LAL captures 10% of AT-IOL market since 2019 launch with strong first-mover advantage. High barriers to entry - took RXST 10+ years to develop, competitors years away from US market entry.
Read full article (1 min)